Maxim Group initiated coverage on Kazia Therapeutics with a new price target
$KZIA
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | $25.00 | Buy | Laidlaw |
| 2/6/2025 | $3.00 | Buy | Maxim Group |
| 10/14/2021 | $18.00 | Buy | Maxim Group |
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies. "James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking," said Dr.
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability DataSYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing Phase 1b clinical trial evaluating lead asset paxalisib in combination with standard-of-care therapies in patients with advanced triple negative breast cancer ("TNBC"). Based on continued encouraging safety, tolerability and clinical activity data observed to date, planned enrollment has increased from 12 to
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Laidlaw initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $25.00
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
3/A - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies. "James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking," said Dr.
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development
SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)